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The trypanosomatid parasite Leishmania infantum is the causative agent of
visceral leishmaniasis (VL), which is usually fatal unless treated. VL has an
incidence of 0.5 million cases every year and is an important opportunistic
co-infection in HIV/AIDS. Tyrosine aminotransferase (TAT) has an important
role in the metabolism of trypanosomatids, catalyzing the first step in the
degradation pathway of aromatic amino acids, which are ultimately converted
into their corresponding l-2-oxoacids. Unlike the enzyme in Trypanosoma cruzi
and mammals, L. infantum TAT (LiTAT) is not able to transaminate
ketoglutarate. Here, the structure of LiTAT at 2.35 A˚ resolution is reported,
and it is confirmed that the presence of two Leishmania-specific residues (Gln55
and Asn58) explains, at least in part, this specific reactivity. The difference
in substrate specificity between leishmanial and mammalian TAT and the
importance of this enzyme in parasite metabolism suggest that it may be a useful
target in the development of new drugs against leishmaniasis.
1. Introduction
The leishmaniases are a group of vector-borne parasitic diseases that
threaten about 350 million people in 88 countries around the world,
mostly in developing countries. Leishmania infantum (family Trypa-
nosomatidae) is the causative agent of zoonotic visceral leishmaniasis
(VL) in the Mediterranean basin, where dogs are the main reservoir.
L. infantum is an important opportunistic human parasite, resulting
in increasing co-infection with HIV (Cruz et al., 2006). A major
outbreak of VL in humans has recently been reported in central
Spain (Arce et al., 2013).
L. infantum has a digenetic biological life cycle, alternating
between a mobile extracellular promastigote in the insect vector
and an immobile intracellular amastigote in the mammalian host
(Handman, 2001). Inside the gut of the sand-fly vector, an environ-
ment rich in proteins and amino acids (Rosenzweig et al., 2008),
promastigotes undergo metacyclogenesis to increase their infectivity,
and differentiate into amastigotes once inside the phagolysosome of
mammalian phagocytes, where the availability of these nutrients is
limited (McConville et al., 2007). Under these conditions, amino-acid
catabolism becomes an important source of energy for the parasite
by cytosolic NADH re-oxidation (Nowicki & Cazzulo, 2008) and
methionine recycling (Berger et al., 2001; Berger et al., 1996).
Aromatic amino-acid catabolism is highly active in trypanosoma-
tids, but degradation to CO2 and water is not complete as in
mammals. This pathway consists of two steps leading to a reduced
l-2-hydroxyacid product whose excretion has been correlated with
virulence (Montemartini et al., 1994). The first step of this pathway is
carried out by a tyrosine aminotransferase (TAT) belonging to the
fold type I aminotransferases within the pyridoxal phosphate (PLP)-
dependent superfamily (Jensen & Gu, 1996). One of the most studied
enzymes belonging to this fold group is the broad substrate-specificity
tyrosine aminotransferase from Trypanosoma cruzi (TcTAT), the
structure of which has recently been resolved (Blankenfeldt et al.,
1999; Montemartini et al., 1993, 1995).
However, the biological function of TAT in trypanosomatids is not
yet clear, although previous studies detected an increase in transcript
abundance of TAT in infective promastigotes of L. infantum (Alcolea
et al., 2009) and in a benznidazole-resistant T. cruzi strain (Rego et al.,
2008). These data suggest that TAT in trypanosomatids may play an
important role in the infectivity of the parasite and its resistance
against chemotherapy. We have solved the structure of L. infantum
tyrosine aminotransferase (LiTAT) covalently bound to PLP,
providing a structural basis for its enzymatic activity. The difference
in substrate specificity between leishmanial and mammalian TATand
the importance of this enzyme in parasite metabolism suggest that it
may be a promising target in the development of new drugs against
leishmaniasis.
2. Methods
2.1. Protein expression and purification
The full-length LiTAT (LinJ.36.2490; NCBI XP_001469829.1) gene
encoding a protein of 448 amino acids (UniProt A4IDL0) was PCR-
amplified from L. infantum (MHOM/ES/98/10445) genomic DNA
using oligonucleotides containing BamHI and HindIII restriction
sites (LiTAT_Fw, 50-ACGGGATCCACGATTGATACGCAGGCC-
30, and LiTAT_Rv, 50-ACGAAGCTTCTACTTCTTGTGGCGCTC-
GC-30). A truncated version of the gene (LiTAT_truncated) lacking
the first 114 nucleotides of the annotated sequence was also amplified
using oligonucleotides containing the same restriction sites
(LiTAT_truncated_Fw, 50-ACGGGATCCACGAGTTTTCGCCGT-
ATCGC-30, and LiTAT_Rv). LiTAT and LiTAT_truncated were
cloned into the pRSET-A vector (Invitrogen) and recombinant
proteins were expressed in Escherichia coli BL21 (DE3) pLysS. Cells
were grown in 3 l LB medium at 310 K until the OD600 reached 0.5.
Isopropyl -d-1-thiogalactopyranoside (IPTG) was then added to a
final concentration of 1 mM and induction continued for 2 h at 298 K,
after which the harvested cells were frozen at 193 K. The frozen cell
pellet was thawed and resuspended by vortexing in 200 ml lysis buffer
[20 mM Tris–HCl pH 7.9, 500 mMNaCl, 4 mM PLP, 50 mM imidazole,
0.05 mg ml1 lysozyme and protease-inhibitor cocktail (Roche, Basel,
Switzerland; used following the manufacturer’s instructions)]. The
cell suspensions were lysed by sonication for 15 min and clarified by
centrifugation on a Sorvall SS-34 at 27 000g. The clarified solutions
were syringe-filtered through a 0.45 mm filter. The proteins were
purified at room temperature by immobilized metal-affinity chro-
matography on a HisTrap FF 5 ml column (GE Healthcare) equili-
brated with binding buffer (20 mM Tris–HCl pH 7.9, 500 mM NaCl,
4 mM PLP, 50 mM imidazole). The proteins were eluted with eight
column volumes of elution buffer (20 mM Tris–HCl pH 7.9, 500 mM
NaCl, 4 mM pyridoxal phosphate, 500 mM imidazole). Size-exclusion
chromatography was performed at room temperature using a HiLoad
26/60 Superdex 75 prep-grade column (GE Healthcare, Piscataway,
New Jersey, USA) equilibrated in SEC buffer [20 mM HEPES pH
7.0, 300 mM NaCl, 5%(v/v) glycerol, 1 mM tris(2-carboxyethyl)-
phosphine hydrochloride]. Both proteins eluted as single peaks which
correspond to the dimeric form in solution based on the estimated
molecular weight. The calibration curve obtained using the Low
Molecular Weight Kit (GE Healthcare) allowed determination of the
molecular weights of both proteins once the gel base distribution
coefficient value (Kav) has been calculated from the measured elution
volume (Supplementary Fig. S11). Pooled fractions were concen-
trated at 277 K using an Amicon Ultra-15 30 kDa molecular-weight
cutoff concentrator (Millipore, Billerica, Massachussets, USA) to
64.6 mg ml1 for LiTAT and 51.6 mg ml1 for LiTAT_truncated. The
purity of both proteins was assessed to be >95% by SDS–PAGE.
2.2. Crystallization and structure solution
Purified LiTAT and LiTAT_truncated proteins were used for
crystallization screening at 21.0 and 21.3 mg ml1, respectively, using
four sparse-matrix screens: JCSG+, MCSG1 (Emerald Bio),
Morpheus and PACT (Molecular Dimensions). Hexagonal crystals
were obtained under several conditions, but few diffracted well.
Crystals of LiTAT_truncated from Morpheus screen condition B11
(10% PEG 4000, 20% glycerol, 30 mM NaF, 30 mM NaBr, 30 mM
NaI, 100 mM Bicine/Tris–HCl pH 8.5) were vitrified by plunging them
into liquid nitrogen. X-ray diffraction data were collected on LS-CAT
beamline 21-ID-Fat the Advanced Photon Source, Argonne National
Laboratory at a temperature of 100 K using a Rayonix MX-225
detector.
The diffraction data were reduced with the XDS suite (Kabsch,
2010) to 2.35 A˚ resolution (Table 1). Molecular replacement was
performed with Phaser (McCoy et al., 2007) using the structure of
TcTAT (PDB entry 1bw0; Blankenfeldt et al., 1999) as the search
model. Molecular-replacement phases were improved including
twofold NCS averaging with Parrot (Cowtan, 2010). An initial model
was then built using Buccaneer (Cowtan, 2006). The model was then
improved using iterative cycles of manual model building in Coot
(Emsley et al., 2010) and refinement with phenix.refine (Adams et al.,
2010). The resolution cutoff was I/(I) > 2 for the highest shell.
Structure factors and coordinates have been deposited in the PDB
as entry 4ix8.
2.3. Determination of the activity of LiTAT_truncated
The activity of LiTAT_truncated was assayed by the method of
Diamondstone (1966) without the addition of diethylthiocarbamate.
One unit of enzyme activity is defined as the amount of LiTAT
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Table 1
Data-collection statistics.
Values in parentheses are for the highest of 20 resolution shells.
Diffraction data
Space group P3221
Unit-cell parameters (A˚) a = b = 98.96, c = 199.26
Resolution (A˚) 50–2.35 (2.41–2.35)




Completeness (%) 99.8 (99.9)
Multiplicity 4.6 (4.7)
No. of unique reflections 47821 (3479)
Wilson B factor (A˚2) 40.4
Refinement
No. of protein atoms 5859
No. of waters 274
No. of other atoms 50
Rwork‡ 0.173 (0.261)
Rfree§ 0.206 (0.325)
R.m.s.d., bonds (A˚) 0.012
R.m.s.d., angles () 1.35
Ramachandran, favoured 745 [97.9%]
Ramachandran, outliers None




MolProbity clashscore} 1.31 [100th percentile]

















hkl jFobsj. § The free R factor was calculated with an equivalent
equation to Rwork using 5% of the reflections that were omitted from the
refinement. } Chen et al. (2010).
1 Supporting information has been deposited in the IUCr electronic archive
(Reference: HV5256).
that catalyzes the formation of 1 mmol p-hydroxyphenylpyruvate
(measured as p-hydroxybenzaldehyde). The final enzymatic activity
values are the means of four determinations.
3. Results and discussion
3.1. Comparison of LiTAT with other closely related
aminotransferases
The primary sequence of the TAT protein is highly conserved
among all Leishmania spp., while orthologues annotated in other
trypanosomatids, such as T. cruzi, T. rangeli and Crithidia acantho-
cephali, show <50% sequence identity to the Leishmania sequence.
L. infantum contains only a single copy of the TAT gene
(LinJ.36.2490), while in T. cruzi there are around 70 copies of the
TcTAT gene (Bontempi et al., 1993). Interestingly, the TAT gene
appears to be absent from the African trypanosomes (such as
T. brucei), which do not have an intracellular immobile stage where
the availability of nutrients is limited. Sequence alignment (Supple-
mentary Fig. S2) shows a low degree of sequence identity between
LiTAT and mammalian liver TAT (37%) and also between LiTAT
and TcTAT (44%). Interestingly, the N-terminal 38 amino acids of
mammalian liver TATwhich were previously proposed to be involved
in the rapid degradation of the protein (Hargrove et al., 1989) are
present in LiTAT (albeit with little sequence conservation) and are
absent from the T. cruzi enzyme.
3.2. Crystal structure of LiTAT
The N-terminal domain was too disordered to be modelled in full-
length LiTAT, but its deletion in LiTAT_truncated did not affect the
overall structure of the protein. Indeed, the best resolution (2.35 A˚)
was achieved for the LiTAT_truncated PLP-bound structure. The
final model has a crystallographic R value of 17.3% and an Rfree value
of 20.3% (Table 1). The asymmetric unit of the crystal in space group
P3221 is formed by two identical polypeptide chains (A and B),
forming a homodimer that is also present in solution (see Supple-
mentary Fig. S1). For chain A residues Ser40–Lys448 could be built,
while for chain B only residues Ser40–Ile439 could be built. However,
several loop regions (Asp62–Asn63 in chain A and Asp62–Ser72,
Glu363–Gly367, Lys382–Ser393 and Glu404–Glu405 in chain B) were
too disordered to be modelled.
The five closest structural homologues of LiTAT were identified
using the DaliLite v.3 server (Holm & Rosenstro¨m, 2010): TcTAT
(PDB entry 1bw0; Z-score 59.2, 44% identity; Blankenfeldt et al.,
1999), TAT from Homo sapiens (PDB entry 3dyd; Z-score 54.4, 37%
identity; Structural Genomics Consortium, unpublished work),
alanine aminotransferase from Pyrococcus furiosus (PDB entry 1xi9;
Z-score 53.1, 28% identity; Southeast Collaboratory for Structural
Genomics, unpublished work), TAT from Mus musculus (PDB entry
3pdx; Z-score 52.8, 38% identity; Mehere et al., 2010) and -amino-
transferase from P. horikoshii (PDB entry 1gd9; Z-score 48.4, 22%
identity; Ura et al., 2001). These alignments show the low percentage
similarity between LiTAT and the other closely related orthologues.
The structure of each LiTAT subunit shows the typical fold type I
of the aminotransferases (McPhalen et al., 1992), with each monomer
having two domains (Fig. 1). The larger of these domains (Asp91–
Arg339) forms an internal core of seven sheets with 2 antiparallel to
the rest. The core of the -sheets is enclosed by -helices. The smaller
discontinuous domain comprises residues from the N-terminus
(Lys65–Pro90) and C-terminus (Thr340–Lys448) which are involved
in substrate recognition. As in TcTAT, the N-terminal residues
(Ser40–Ser47) of LiTAT_truncated are involved in interaction
between subunits (Blankenfeldt et al., 1999).
LiTAT contains 13 cysteine residues per subunit; however, there
are no disulfide bonds. Thus, it appears that the disulfide bond-
mediated inactivation observed for mammalian TATs (Mehere et al.,
2010) is not used in LiTAT.
3.3. Substrate recognition
Reversible transamination reactions are a bi-bi ping-pong
mechanism (Kirsch et al., 1984), and tyrosine aminotransferases
catalyze the transamination of an amino group from the donor to
structural communications
Acta Cryst. (2014). F70, 583–587 Moreno et al.  Tyrosine aminotransferase 585
Figure 1
Dimeric crystal structure of LiTAT solved at 2.35 A˚ resolution. -Sheets and
-helices are shown as ice-blue and red ribbons for subunit A and as cyan and
yellow ribbons for subunit B, respectively. The PLP molecule bound to Lys286 in
each subunit is highlighted as a sphere model with C atoms in green.
Figure 2
Transamination in two steps between tyrosine as the amino donor and pyruvate as the amino acceptor catalyzed by LiTAT. The end products of the reaction are alanine and
p-hydroxyphenylpyruvate (HPP); the latter is reduced to p-hydroxyphenyllactate by a dehydrogenase in trypanosomatids.
the covalently bound PLP to form pyridoxamine phosphate (PMP;
Fig. 2). The second step of the reaction transfers the amino group to
the carbonyl moiety of an amino acceptor, regenerating the pros-
thetic group. In both subunits of LiTAT, PLP is covalently bound to
Lys286 in a cavity located at the interface between the subunits,
although these cavities are not adjacent in the dimer (Fig. 3).
However, residues from both subunits participate in the stabilization
of PMP and their disposition is similar between LiTAT and TcTAT,
although Thr184 and Tyr345 in TcTAT are replaced by Ile221 and
Phe378 in LiTAT. Since the hydroxyl group of Tyr345 is oriented
towards the internal aldimine, replacement by Phe378 in LiTAT may
affect the reactivity of PLP with the amino donor and/or acceptor.
Unlike TcTAT (and mammalian TATs), LiTAT is not able to
transaminate -ketoglutarate using tyrosine as the amino donor (0.32
 0.17 U per milligram of purified protein), although it can transa-
minate pyruvate with high efficiency (82.3  0.79 U per milligram
of purified protein), consistent with the published activity of the
L. major orthologue (Marciano et al., 2009).
Site-directed mutagenesis studies using rat TAT and TcTAT
showed that the ability to transaminate dicarboxylic substrates was
likely to be owing to the presence of residues Asn54 and Arg57
(Asn17 and Arg20 in TcTAT) helping to orient the amino acceptors
towards the active centre (Sobrado et al., 2003). These residues, which
are conserved in most orthologues of tyrosine aminotransferases, are
not present in LiTAT, where they are replaced by Gln55 and Asn58.
While the side chain of Asn58 was not well resolved in our model, the
side chain of Gln55 is less oriented towards the substrate-binding
pocket than Asn17 in TcTAT (Fig. 4). Thus, we postulate that the
difference in the specificity of Leishmania TATs is related to these
amino-acid substitutions by altering the hydrogen-bonding inter-
action with the oxoacid substrates.
4. Conclusion
We have obtained a 2.35 A˚ resolution structure of tyrosine amino-
transferase from L. infantum, which correlates well with those of
other tyrosine aminotransferases. However, unlike other amino-
transferases, Leishmania TAT is not able to transaminate dicarboxylic
substrates and its preferred substrate is pyruvate. This can be
explained by the substitution of the critical residues Asn54 and Arg57
found in other TAT orthologues by Gln55 and Asn58 in LiTAT. This
difference in substrate activity, as well as the relevance of the enzyme
to the life cycle of the parasite, highlight the importance of this
enzyme as a potential candidate for the development of inhibitors in
the near future.
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